SCHEMBL5136944

SCHEMBL5136944

CCCCn1c(-c2ccccc2)nc(-c2ccccc2)c1CN(Cc1ccccc1)Cc1ccc(F)cc1F

nearest known ligand 0.44

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
C5AR1 P21730 1/20 0.44
TSHR P16473 2/20 0.39
CYP19A1 P11511 1/20 0.39
P2RX7 Q99572 3/20 0.37
NPC1 O15118 1/20 0.35
RAB9A P51151 1/20 0.35
CRHR1 P34998 2/20 0.35
NR3C1 P04150 1/20 0.35
MEN1 O00255 1/20 0.35
KMT2A Q03164 1/20 0.35
KDM4E B2RXH2 1/20 0.34
ALDH1A1 P00352 1/20 0.34
HPGD P15428 1/20 0.34
HSD17B10 Q99714 1/20 0.34
PDE4B Q07343 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5135688 0.93 C5AR1 (0.45) C5AR1TSHRP2RX7NPC1RAB9A
SCHEMBL5136710 0.92 C5AR1 (0.42) C5AR1TSHRCYP19A1KDM4EALDH1A1
SCHEMBL5135670 0.91 C5AR1 (0.43) C5AR1TSHRCYP19A1P2RX7NPC1
SCHEMBL5136299 0.90 C5AR1 (0.45) C5AR1TSHRCYP19A1CRHR1MEN1
SCHEMBL649714 0.90 C5AR1 (0.43) C5AR1TSHRCRHR1KDM4EALDH1A1
SCHEMBL5072370 0.89 C5AR1 (0.47) C5AR1TSHRKDM4EALDH1A1HPGD
SCHEMBL5136224 0.89 C5AR1 (0.41) C5AR1TSHRP2RX7NPC1RAB9A
SCHEMBL5136102 0.88 C5AR1 (0.39) C5AR1TSHRCYP19A1P2RX7NPC1
SCHEMBL651777 0.87 C5AR1 (0.46) C5AR1TSHRP2RX7CRHR1MEN1
SCHEMBL651094 0.87 TSHR (0.50) C5AR1TSHRKDM4EALDH1A1HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1490044-A4 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORP (US) 2008-04-16 EP disclosed
EP-1490044-A1 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORPORATION (US) 2004-12-29 EP disclosed
WO-2003084524-A1 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORPORATION (US) 2003-10-16 WO disclosed